As per the SNS Insider report titled, Gene Expression Analysis Market Size, Share & Segmentation By Product, Technology, Application, End User, and Region | Global Forecast 2026–2035 “The global Gene Expression Analysis Market is valued at USD 4.72 Billion in 2025 and is expected to reach USD 11.53 Billion by 2035, growing at a CAGR of 9.33% over the forecast period of 2026-2035.”
As per industry analysis, the growing trend towards the use of precision medicines, fast growth in next-generation sequencing techniques, increased investments in oncology research, and increased demand for transcriptomics diagnosis services have been fueling global market growth.
The analysis of gene expression has emerged as an indispensable tool in molecular biology, diagnostics in oncology, biomarkers identification, drug discovery, and personalized medicine. Modern genomics tools such as RNA sequencing, real-time polymerase chain reaction, microarray analysis, and single cell transcriptomics play a significant role in advancing profiling techniques and making better decisions about therapies.
Rising Precision Medicine Initiatives and Expansion of Genomic Research Programs Accelerate Market Growth
Rising interest in precision medicine and translational genomics in the global community is one of the leading factors contributing to the growth in the gene expression analysis market. Significant investments are being made by various governments in the development of genomics facilities and large-scale sequencing projects. As per National Human Genome Research Institute (NHGRI), the world will be able to produce more than an exabyte of genomic data within the next decade due to the proliferation of clinical sequencing applications and the use of biomarkers in cancer research.
Moreover, rising incidences of cancer and other chronic conditions around the globe are adding to the demand for gene expression profiling solutions. The World Health Organization (WHO) stated that cancer led to the death of about 10 million people worldwide in 2024. Gene expression analysis is highly useful for biomarker identification, assessment of the genetic heterogeneity of cancer, immune response analysis, and finding possible treatment options for various cancer types such as breast, lung, colorectal, and hematological cancers.
In addition, advances in next-generation sequencing technologies are providing new opportunities in the field of transcriptomics as they can analyze samples quickly and accurately and can provide insights into complex diseases. Sequencing has become much cheaper within the past decade, thereby making it feasible for clinical purposes. Besides, the use of artificial intelligence and bioinformatics tools is contributing to advancements in transcriptome analysis.
Nevertheless, high pricing of instruments, difficulties in interpreting genomic data, scarcity of skilled bioinformatics experts, and challenges associated with regulatory policies regarding genomic data management act as barriers to growth in emerging economies.
Key Report Highlights
- By Product, Reagents dominated the market with a share of 58% in 2025 due to recurring demand for sequencing kits, PCR consumables, enzymes, probes, and assay reagents across research and clinical workflows. Services are expected to witness the fastest growth during 2026-2035, supported by increasing outsourcing of genomic testing and bioinformatics analysis.
- By Technology, PCR accounted for the largest revenue share of 44% in 2025 owing to its widespread use in gene quantification, infectious disease testing, and oncology applications. Next-Generation Sequencing (NGS) is projected to emerge as the fastest-growing technology segment during the forecast period due to rising adoption of RNA sequencing and single-cell transcriptomics.
- By Application, Research Applications held the largest market share of 48% in 2025 driven by expanding genomics research funding and transcriptomic studies across academic institutions and biotechnology companies. Clinical Diagnostics is expected to register the fastest growth during 2026-2035 with increasing use of molecular diagnostics and companion diagnostics.
- By End User, Pharmaceutical Companies accounted for the largest market share of 41% in 2025 due to growing utilization of gene expression analysis in drug discovery, biomarker identification, and clinical trial stratification. Diagnostic Laboratories are projected to witness the fastest growth through 2035 owing to increasing adoption of precision diagnostics and genomic testing services.
- Regionally, North America dominated the Gene Expression Analysis Market with a market share of 38% in 2025, supported by advanced genomic infrastructure, strong biotechnology investments, and large-scale precision medicine initiatives. Asia Pacific is projected to be the fastest-growing regional market with a CAGR of 13.32% from 2026-2035.
Regional Outlook:
The gene expression analysis market in North America captured the highest share in 2025, accounting for 38%. This is attributed to increased investment in genomics research, well-established healthcare infrastructure, and adoption of precision medicine technologies. Key drivers behind the growth include presence of several leading genomic technology companies, presence of extensive research programs on cancer diseases, and strong funding support from institutions, such as the National Institutes of Health (NIH) and National Cancer Institute (NCI).
As per NIH funding records, the U.S. Government spent over USD 47 billion on medical and genomic research initiatives in 2025. The US is expected to dominate North America due to growing use of RNA sequencing, molecular diagnostics, and companion diagnostics in various therapeutic areas, including rare disease, oncology, and cancer.
Asia Pacific will be the most attractive regional market with respect to CAGR from 2026-2035, expanding at a CAGR of 13.32% during the forecast period. Key factors driving the growth of Asia Pacific market include rising healthcare expenditure, growth of biotechnology sectors, rising number of genomic sequencing activities, and increase in government initiatives for development of precision medicine technologies. Several countries in Asia Pacific region, such as China, India, Japan, and South Korea, have been developing their genomic research capabilities significantly.
China continues to rise as one of the biggest players in the field of genomics with massive investments in large scale sequencing projects and genomic tools and equipment. India too witnesses rising contribution with growth of biotech industry, rising adoption of molecular diagnostic techniques, and increase in collaborations with academics on cancer genomics studies.
Recent Industry Developments:
- In March 2025, Illumina Inc. announced expanded clinical research collaborations to accelerate RNA sequencing applications in oncology biomarker discovery and precision medicine initiatives.
- In January 2025, Thermo Fisher Scientific Inc. introduced advanced transcriptomics workflow solutions designed to improve automation and throughput efficiency in gene expression analysis laboratories.
- In June 2024, Oxford Nanopore Technologies plc expanded its long-read sequencing capabilities for real-time transcriptome analysis and single-cell sequencing applications.
- In April 2024, QIAGEN N.V. launched enhanced bioinformatics software tools to improve interpretation accuracy for RNA sequencing and gene expression datasets in clinical research environments.
Leading Companies in the Gene Expression Analysis Market:
- 10x Genomics Inc.
- Agilent Technologies Inc.
- BGI Genomics Co., Ltd.
- Bio-Rad Laboratories Inc.
- Eurofins Scientific SE
- F. Hoffmann-La Roche Ltd.
- GE HealthCare Technologies Inc.
- GenScript Biotech Corporation
- Illumina Inc.
- Luminex Corporation
- Merck KGaA
- NanoString Technologies Inc.
- Oxford Nanopore Technologies plc
- Pacific Biosciences of California Inc.
- Promega Corporation
- QIAGEN N.V.
- Revvity Inc.
- Standard BioTools Inc.
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
About the Author
Get in touch
